Summary: Watmind USA received FDA Emergency Use Authorization for its SpeedySwab Covid + FLU A&B Self-Test, offering a rapid, over-the-counter solution for detecting COVID-19, Influenza A, and Influenza B at home.

Takeaways

  1. Rapid At-Home Testing Solution: The SpeedySwab test allows individuals aged 2 and older to quickly and easily determine if their symptoms are due to COVID-19, Influenza A, or Influenza B, using advanced Lateral Flow Assay (LFA) technology.
  2. FDA Emergency Use Authorization: This approval underscores the test’s reliability and effectiveness, aligning with broader public health efforts to provide accessible diagnostic tools during flu season and potential COVID-19 surges.
  3. Partnership and Innovation: Developed in collaboration with the National Institutes of Health’s RADx ITAP, the SpeedySwab test represents a significant milestone in at-home diagnostics, empowering individuals to manage their health proactively and reduce disease spread.

Watmind USA, a provider of health diagnostic testing solutions, received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its advanced SpeedySwab Covid + FLU A&B Self-Test for use over-the-counter (OTC) and at the point-of-care (POC). 

This provides a rapid solution for at-home testing that simultaneously detects COVID-19, Influenza A, and Influenza B. The test was developed in partnership with the National Institutes of Health’s Rapid Acceleration of Diagnostics (RADx) Independent Test Assessment Program (ITAP).

The SpeedySwab OTC Test

Watmind USA’s mission is to revolutionize at-home diagnostics. The SpeedySwab OTC test is designed to help symptomatic individuals aged 2 and older quickly identify whether their symptoms are due to COVID-19, Influenza A, or Influenza B. Using a user-friendly step-by-step process, the test employs state-of-the-art Lateral Flow Assay (LFA) technology. This cost-effective advancement is particularly timely as the overlapping symptoms of these viruses can make it challenging to distinguish between them.

Further reading: The Benefits of Home Testing for COVID Immunity, Booster Decisions

“Receiving the EUA for our SpeedySwab test marks a significant milestone in our commitment to advancing public health,” says Dan Davis, CEO of Watmind USA. “As we navigate the ongoing challenges of COVID-19 and influenza A&B strains, our goal is to provide accessible and rapid at-home testing solutions that empower individuals to proactively manage their health from the comfort of their homes, while minimizing the spread of such diseases. Watmind USA is proud to support critical public health initiatives.”

The support for such innovative diagnostic tools aligns with broader efforts to enhance the availability of testing options, especially during flu season and potential COVID-19 surges.

Featured image: The SpeedySwab OTC test is designed to help symptomatic individuals aged 2 and older quickly identify whether their symptoms are due to COVID-19, Influenza A, or Influenza B. Photo: Watmind USA